Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
February 2016
-
Media ReleaseNovartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult…
-
Media ReleaseAlcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.Acquisition to add minimally-invasive glaucoma surgery (MIGS) device to pipeline, expanding Alcon's surgical presence in a new category to treat glaucoma The goal of MIGS is to reduce or…
-
Tailoring tactics to tackle chronic disease in low-income countries
Healthcare expert Dr. Jonathan D. Quick discusses solutions to address the rapid rise of chronic illnesses in the developing world.
-
In The NewsJoe Jimenez on how to improve healthcareIn an op ed with Foreign Affairs, Joe Jimenez explains why outcomes, innovation and collaboration are the keys to improving healthcare worldwide.
-
Rediscovering the power of nature’s exquisite complexity
Read how nature's medicine chest empowers our drug discovery chemists to advance biomedical research
-
Media ReleaseSandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEASandoz acquires rights to PF-06438179 (biosimilar infliximab) in the European Economic Area (EEA)* Sandoz plans to complete Phase III development program and file for registration in the EU…
-
Intractable tumor cells crippled
Functional genomics study reveals a potential approach for tackling glioblastoma, pancreatic cancer and other tumors.
-
Media ReleaseSandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastimSandoz' late-stage biosimilar pipeline gains momentum with sustained investment - five of 10 planned regulatory filings achieved Sandoz believes that the totality of evidence in its submission,…
-
Leveraging the liver’s ability to heal scarred tissue
A reversal in thinking about the reversibility of liver damage is changing the field of hepatology.
-
Featured NewsInnovation in practice: how we form partnerships in pharma
The Novartis Business Development and Licensing team is behind many of the partnerships that fuel our innovation.
-
Opening chemistry education to the world
Novartis taps MOOC technology to share chemistry education with the world
-
Neuroscientists restore cell-to-cell signaling and sociability in autism models
Team uncovers a potential therapeutic approach for patients deficient in a protein called Shank3.
Pagination
- ‹ Previous page
- 1
- …
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- …
- 152
- › Next page